Pharmacotherapeutic Potential and Clinical Efficacy of Microbiota in Metabolic Disorders

Gut microbiota is an essential part of our body as it plays an important physiological role in energy make out and local and systemic immunity control. Over the past two decades, considerable effort has been made to explain the standard microbiota and how it changes in various diseases states. Additionally, disruptions to the gut microbiota seem to have a role in the etiology of a variety of illnesses, like cancer, GI disorders, metabolic disorders, and cardiometabolic diseases. From the perspective of metabolism, gut microbiota can control the generation of short-chain fatty acids, lipopolysaccharide content, and lipid accumulation, which can influence insulin signaling, inflammatory tone, and food intake. Also, it can give contribution to inflammatory responses as microbiologically produced products (metabolites) and molecules can potentially modulate heart-metabolic disorders. A number of methods have been established to alter the gut microbiota, with varying effects on the body’s metabolism. These methods include the use of prebiotics, probiotics, some antidiabetic medications, and fecal microbiota transplantation and the development of metabolic diseases. New research has shown us that microbiota composition is changed in several disease conditions and can give contribution to cardiometabolic disease. They have also shown how gut bacteria can be targeted to treat and prevent metabolic diseases.